European Journal of Cancer最新文献

{"title":"Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: Analysis of a real-world database","authors":"Jialing Neo ,&nbsp;Enya H.W. Ong ,&nbsp;Xin Zhang ,&nbsp;Wen Min Chow ,&nbsp;Joseph T.S. Wee ,&nbsp;Kam Weng Fong ,&nbsp;Yoke Lim Soong ,&nbsp;Terence W.K. Tan ,&nbsp;Jianjun Liu ,&nbsp;Kwok Seng Loh ,&nbsp;Joshua K. Tay ,&nbsp;Mei Kim Ang ,&nbsp;Sze Huey Tan ,&nbsp;Darren W.T. Lim ,&nbsp;Melvin L.K. Chua","doi":"10.1016/j.ejca.2025.115396","DOIUrl":"10.1016/j.ejca.2025.115396","url":null,"abstract":"<div><h3>Aim</h3><div>Plasma Epstein-Barr virus (EBV) DNA is an archetypal biomarker for endemic nasopharyngeal carcinoma (NPC) employed for disease surveillance and early detection of recurrences. However, its accuracy is unknown. We utilised a single institution dataset with homogeneous surveillance procedures and routine EBV DNA testing using a harmonised assay to investigate its accuracy for recurrence detection.</div></div><div><h3>Methods</h3><div>We utilised a cohort of patients with histologically-confirmed, non-metastatic NPC treated from February, 2017 to July, 2023. All patients had ≥ 1 EBV DNA test using the harmonised <em>Bam</em>HI-W polymerase chain reaction-based assay within 3 years post-radiotherapy (RT). We analysed the negative (NPV) and positive predictive values (PPV) for recurrence over a 1-year window (at 3-monthly intervals – windows 1–4) for each test performed. Recurrence was ascertained by radiological imaging and/or histopathological confirmation.</div></div><div><h3>Results</h3><div>Of 1746 EBV DNA readings from 393 patients diagnosed between January, 2017 to May, 2023, 1385 (79.3 %), 294 (16.8 %), and 67 (3.9 %) were recorded as negative, low (&lt; 500 copies/mL), and high EBV DNA (≥ 500 copies/mL), respectively. NPVs of the assay were high (range: 97.6–99.3 %). PPVs were modest, highest at window 1 (range: 26.3–34.3 %) compared with the other 3 windows (range: 2.6–10.5 %). Sensitivity analyses revealed that PPVs were threshold-dependent; 71.4–100 % at window 1 for ≥ 500 copies/mL versus 16.9–23.1 % for &lt; 500 copies/mL, which corresponded to median time of recurrence onset (0.8 <em>vs</em> 4.8 months, respectively).</div></div><div><h3>Conclusions</h3><div>Negative EBV DNA test results have high NPVs, suggesting that patients may be routinely surveyed, while a positive result of ≥ 500 copies/mL indicates high recurrence risk.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115396"},"PeriodicalIF":7.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on the role of “-Omics” in predicting response to immunotherapy","authors":"Anna Maria Di Giacomo ,&nbsp;Sumit Subudhi ,&nbsp;Wim Vos ,&nbsp;Massimo Andreatta ,&nbsp;Santiago Carmona ,&nbsp;Will McTavish ,&nbsp;Barbara Seliger ,&nbsp;Ramy Ibrahim ,&nbsp;Michael Lahn ,&nbsp;Michael Smith ,&nbsp;Alexander Eggermont ,&nbsp;Bernard A. Fox ,&nbsp;Michele Maio","doi":"10.1016/j.ejca.2025.115393","DOIUrl":"10.1016/j.ejca.2025.115393","url":null,"abstract":"<div><div>The annual Immuno-Oncology “Think Tank” held in October 2023 in Siena reviewed the rapidly evolving systems-biological approaches which are now providing a deeper understanding of tumor and tumor microenvironment heterogeneity. Based on this understanding opportunities for novel therapies may be identified to overcome resistance to immunotherapy. There is increasing evidence that malignant disease processes are not limited to purely intracellular or genetic events but constitute a dynamic interaction between the host and disease. Tumor responses are influenced by many host tissue determinants across different cellular compartments, which can now be investigated by high-throughput molecular profiling technologies, often labelled with a suffix “-omics”. “Omics” together with ever increasing computational power, fast developments in machine learning, and high-resolution detection tools offer an unrivalled opportunity to connect high-dimensional data and create a holistic view of disease processes in cancer. This review describes advances in several state-of-the-art “-omics” approaches with perspectives on how these can be applied to the clinical development of new immunotherapeutic strategies and ultimately adopted in clinical practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115393"},"PeriodicalIF":7.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daratumumab for high-risk smoldering multiple myeloma – Are we there yet?","authors":"Bhavesh Mohan Lal,&nbsp;Samer Al Hadidi","doi":"10.1016/j.ejca.2025.115391","DOIUrl":"10.1016/j.ejca.2025.115391","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115391"},"PeriodicalIF":7.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT)","authors":"Javier Gavira ,&nbsp;Edouard Auclin ,&nbsp;Macarena Rey-Cardenas ,&nbsp;Pritha Roy ,&nbsp;Jose C. Tapia ,&nbsp;Paula Nay ,&nbsp;Armelle Vinceneux ,&nbsp;Felix Lefort ,&nbsp;Simon Nannini ,&nbsp;Adela Maria del Carmen Randis ,&nbsp;Natacha Naoun ,&nbsp;Bernard Escudier ,&nbsp;Delphine Borchiellini ,&nbsp;Guillermo de Velasco ,&nbsp;Philippe Barthelemy ,&nbsp;Marine Gross-Goupil ,&nbsp;Sylvie Negrier ,&nbsp;Stéphane Oudard ,&nbsp;Ricky D. Frazer ,&nbsp;Laurence Albiges ,&nbsp;Ronan Flippot","doi":"10.1016/j.ejca.2025.115389","DOIUrl":"10.1016/j.ejca.2025.115389","url":null,"abstract":"<div><h3>Background and Objective</h3><div>Lenvatinib’s activity after immune checkpoint inhibitors (ICI) combination therapy in renal cell carcinoma (RCC) remains unknown. We aimed to describe the real-world outcomes of patients with metastatic RCC (mRCC) treated with lenvatinib after failure of the prior standard of care.</div></div><div><h3>Methods</h3><div>Multicenter retrospective study including patients with mRCC treated with lenvatinib-based therapies beyond first-line therapy between 2020 and 2024. The primary endpoints were objective response rate (ORR) and time-to-treatment failure (TTF). Secondary endpoints included disease control rate (DCR), overall survival (OS), and safety.</div></div><div><h3>Results</h3><div>We included 133 patients, with a median age of 61 years. Clear-cell was the main subtype (82.0 %). Before lenvatinib treatment, 15.8 %, 51.9 %, and 27.8 % of patients showed favorable, intermediate, and poor risk disease, respectively, according to the International Metastatic RCC Database Consortium (IMDC). Moreover, patients received a median of 3 previous lines of treatment, including ICIs (90.2 %) and cabozantinib (90.2 %). Lenvatinib was given alone (45.9 %) or in combination with everolimus (33.8 %), pembrolizumab (18.0 %) or investigational agents (2.3 %). The ORR and DCR were 29.1 % and 67.7 %, respectively, with no differences between regimens or lines of treatment. With a median follow-up time of 13.5 months, the median TTF and OS were 6.2 and 9.6 months. Toxicity was manageable with dose modifications required in 34.6 %. The discontinuation rate was 9.8 %, with one toxic death.</div></div><div><h3>Conclusion</h3><div>Lenvatinib-based regimens were active and safe for heavily pre-treated patients with mRCC. These findings provide evidence to support its use in daily practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115389"},"PeriodicalIF":7.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-based virtual staining platform for identifying tumor-associated macrophages from hematoxylin and eosin-stained images","authors":"Arpit Aggarwal ,&nbsp;Mayukhmala Jana ,&nbsp;Amritpal Singh ,&nbsp;Tanmoy Dam ,&nbsp;Himanshu Maurya ,&nbsp;Tilak Pathak ,&nbsp;Sandra Orsulic ,&nbsp;Kailin Yang ,&nbsp;Deborah Chute ,&nbsp;Justin A. Bishop ,&nbsp;Farhoud Faraji ,&nbsp;Wade M. Thorstad ,&nbsp;Shlomo Koyfman ,&nbsp;Scott Steward ,&nbsp;Qiuying Shi ,&nbsp;Vlad Sandulache ,&nbsp;Nabil F. Saba ,&nbsp;James S. Lewis Jr. ,&nbsp;Germán Corredor ,&nbsp;Anant Madabhushi","doi":"10.1016/j.ejca.2025.115390","DOIUrl":"10.1016/j.ejca.2025.115390","url":null,"abstract":"<div><h3>Background</h3><div>Virtual staining is an artificial intelligence-based approach that transforms pathology images between stain types, such as hematoxylin and eosin (H&amp;E) to immunohistochemistry (IHC), providing a tissue-preserving and efficient alternative to traditional IHC staining. However, existing methods for translating H&amp;E to virtual IHC often fail to generate images of sufficient quality for accurately delineating cell nuclei and IHC+ regions. To address these limitations, we introduce VISTA, an artificial intelligence-based virtual staining platform designed to translate H&amp;E into virtual IHC.</div></div><div><h3>Methods</h3><div>We applied VISTA to identify M2-subtype tumor-associated macrophages (M2-TAMs) in H&amp;E images from 968 patients with HPV+ oropharyngeal squamous cell carcinoma across six institutional cohorts. M2-TAMs are a critical component of the tumor microenvironment, and their increased presence has been linked to poor survival. Co-registered H&amp;E and CD163 + IHC tissue microarrays were used to train (D1, N = 102) and test (D2, N = 50) the VISTA platform. M2-TAM density, defined as the ratio of M2-TAMs to total nuclei, was derived from VISTA-generated CD163 + IHC images and evaluated for prognostic significance in additional training (D3, N = 360) and testing (D4, N = 456) cohorts using biopsy or resection H&amp;E whole slide images.</div></div><div><h3>Results</h3><div>High M2-TAM density was associated with worse overall survival in D4 (p = 0.0152, Hazard Ratio=1.63 [1.1–2.42]). VISTA outperformed existing methods, generating higher-quality virtual CD163 + IHC images in D2, with a Structural Similarity Index of 0.72, a Peak Signal-to-Noise Ratio of 21.5, and a Fréchet Inception Distance of 41.4. Additionally, VISTA demonstrated superior performance in segmenting M2-TAMs in D2 (Dice=0.74).</div></div><div><h3>Conclusion</h3><div>These findings establish VISTA as a computational platform for generating virtual IHC and facilitating the discovery of novel biomarkers from H&amp;E images.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115390"},"PeriodicalIF":7.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between premature menopause and the risk of biliary tract cancer: A nationwide cohort study","authors":"Chi Hoon Maeng ,&nbsp;Kyungdo Han ,&nbsp;Jung Yong Hong ,&nbsp;Joo-Hyun Park","doi":"10.1016/j.ejca.2025.115387","DOIUrl":"10.1016/j.ejca.2025.115387","url":null,"abstract":"<div><h3>Introduction</h3><div>Recent studies indicate a potential link between female reproductive factors and the risk of biliary tract cancer (BTC). However, this association remains controversial due to conflicting results, highlighting the need for further investigation into hormonal influences on BTC development.</div></div><div><h3>Methods</h3><div>We conducted a nationwide cohort study using data from the Korean National Health Insurance System, following 1059,533 menopausal women aged 40–69 years (median follow-up: 9.3 years). Cox proportional hazards regression was applied to assess the risk of cholangiocarcinoma (CCA) and gallbladder cancer (GBC) in relation to reproductive factors, particularly premature menopause (before age 40) and total reproductive period (time from menarche to menopause). The primary outcome was the incidence of BTC, specifically CCA and GBC.</div></div><div><h3>Results</h3><div>During 9.87 million person-years of follow-up, 4198 women (0.40 %) were diagnosed with BTC. Premature menopause was associated with a significant increase in risk for both CCA (adjusted HR 1.29, 95 % CI: 1.01–1.64) and GBC (adjusted HR 1.42, 95 % CI: 1.03–1.97). A shorter total reproductive period (&lt;30 years) was associated with a higher risk of BTC, with an adjusted HR of 1.10 (95 % CI: 0.99–1.21) for CCA and 1.15 (95 % CI: 1.01–1.33) for GBC. Other female reproductive factors assessed showed no significant associations.</div></div><div><h3>Conclusions</h3><div>Premature menopause is associated with an increased risk of BTC, suggesting reduced lifetime exposure to female hormones as a risk factor. These results highlight the importance of considering reproductive history in identifying high-risk women and may inform targeted screening strategies for early detection.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115387"},"PeriodicalIF":7.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Re-re-treatment?\" Third and fourth courses of BRAF/MEK inhibition in advanced melanoma.","authors":"Michael T O'Brien, Sage Iwamoto, Rizwan Haq, Douglas B Johnson","doi":"10.1016/j.ejca.2025.115378","DOIUrl":"https://doi.org/10.1016/j.ejca.2025.115378","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":" ","pages":"115378"},"PeriodicalIF":7.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters","authors":"Julian Walter Holch ,&nbsp;Alexander J. Ohnmacht ,&nbsp;Sebastian Stintzing ,&nbsp;Kathrin Heinrich ,&nbsp;Lena Weiss ,&nbsp;Victoria Probst ,&nbsp;Arndt Stahler ,&nbsp;Ludwig Fischer von Weikersthal ,&nbsp;Thomas Decker ,&nbsp;Alexander Kiani ,&nbsp;Florian Kaiser ,&nbsp;Tobias Heintges ,&nbsp;Christoph Kahl ,&nbsp;Frank Kullmann ,&nbsp;Hartmut Link ,&nbsp;Heinz-Gert Höffkes ,&nbsp;Markus Moehler ,&nbsp;Dominik Paul Modest ,&nbsp;Michael P. Menden ,&nbsp;Volker Heinemann","doi":"10.1016/j.ejca.2025.115388","DOIUrl":"10.1016/j.ejca.2025.115388","url":null,"abstract":"<div><h3>Background</h3><div>Primary tumor sidedness (PTS) with discrimination of left-sided (LC) and right-sided tumors (RC) guides patient selection for targeted first-line therapy in <em>RAS</em> wild-type (<em>RAS-</em>WT) metastatic colorectal cancer (mCRC). This study assessed the hypothesis whether considering PTS with additional clinical parameters better predicts the treatment benefit of targeted first-line treatment.</div></div><div><h3>Methods</h3><div>In FIRE-3, first-line treatment with folinic acid, fluorouracil and irinotecan (FOLFIRI) plus cetuximab (FOLFIRI/Cet) was compared to FOLFIRI plus bevacizumab (FOLFIRI/Bev) in patients with <em>RAS</em>-WT mCRC and unresectable metastasis. We evaluated whether combining PTS with number of metastatic sites (NOM), liver-limited disease status (LLD), age, sex, or carcinoembryonic antigen level (CEA) better predicts treatment benefit regarding overall survival (OS). Here, Cox regression models with second-order interactions were applied. Further, the results were validated by policy learning and Lasso regression analysis.</div></div><div><h3>Findings</h3><div>Among 400 <em>RAS</em>-WT mCRC patients, combining PTS with LLD status in a Cox regression model outperformed PTS alone for predicted treatment benefit (P = 0·005; c‑index=0·603). Significant OS benefit from FOLFIRI/Cet over FOLFIRI/Bev was observed in LC/non-LLD patients (HR=0·62; 95 %-confidence interval [CI]=0·46–0·82; P = 0·002), but mitigated in LC/LLD patients (HR=0·83; 95 %-CI=0·53–1·29; P = 0·400). In RC/non-LLD patients, FOLFIRI/Bev demonstrated a significant OS advantage over FOLFIRI/Cet (HR=2·09; 95 %‑CI=1·20–3·63; P = 0·010). However, RC/LLD patients showed potential benefit from FOLFIRI/Cet, though not statistically significant (HR=0·59; 95 %-CI=0·25–1·39; P = 0·218).</div></div><div><h3>Interpretation</h3><div>Incorporating PTS and LLD status might improve selection of targeted first-line treatment in <em>RAS</em>-WT mCRC patients. FOLFIRI/Cet appears to be particularly beneficial for LC/non-LLD patients with mitigated benefit in patients with LC/LLD. In contrast, FOLFIRI/Bev is significantly favoured over FOLFIRI/Cet in patients with RC/non-LLD. Notably, RC/LLD patients may still benefit from anti-EGFR therapy despite right-sided primary tumor. These results are hypothesis-generating and warrant further validation.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115388"},"PeriodicalIF":7.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matching-adjusted indirect comparison of endoscopic and craniofacial resection for the treatment of sinonasal cancer invading the skull base","authors":"Florian Chatelet ,&nbsp;Sylvie Chevret ,&nbsp;Alessandro Vinciguerra ,&nbsp;Giacomo Bertazzoni ,&nbsp;Domitille Camous ,&nbsp;Marco Ferrari ,&nbsp;Davide Mattavelli ,&nbsp;Mario Turri-Zanoni ,&nbsp;Alberto Schreiber ,&nbsp;Stefano Taboni ,&nbsp;Vittorio Rampinelli ,&nbsp;Alberto Daniele Arosio ,&nbsp;Cesare Piazza ,&nbsp;Paolo Battaglia ,&nbsp;Maurizio Bignami ,&nbsp;Alberto Deganello ,&nbsp;Paolo Castelnuovo ,&nbsp;Piero Nicolai ,&nbsp;Philippe Herman ,&nbsp;Benjamin Verillaud","doi":"10.1016/j.ejca.2025.115382","DOIUrl":"10.1016/j.ejca.2025.115382","url":null,"abstract":"<div><h3>Aim</h3><div>The aim of this study was to compare the efficacy and safety of endoscopic endonasal approaches (EEA) with craniofacial resection (CFR) for sinonasal cancers invading the skull base, using an unanchored matching-adjusted indirect comparison (MAIC).</div></div><div><h3>Methods</h3><div>A MAIC approach was used to analyse data from two large cohorts: the MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers (MUSES) cohort, comprising sinonasal cancer patients treated endoscopically, and a historical CFR cohort reported by Ganly et al. Individual patient data were available only for the first cohort. Patients with olfactory neuroblastomas were excluded. Key prognostic factors were used to match and adjust the two cohorts, minimising selection bias. The primary endpoint was overall survival (OS), with secondary endpoints including recurrence-free survival (RFS), perioperative mortality, complication rates, and resection margins.</div></div><div><h3>Results</h3><div>A total of 724 EEA-treated and 334 CFR-treated patients were included. EEA showed significantly improved OS before (HR= 2.33, 95 % CI= 1.88–2.87) and after MAIC adjustment (HR= 1.93, 95 % CI= 1.60–2.34). Observed RFS was higher in the EEA group (HR= 1.39, 95 % CI = 1.14–1.69) but no longer differed after adjustment (HR= 1.06, 95 % CI= 0.91–1.23). EEA was associated with significantly better Disease Specific Survival (HR= 1.71, 95 % CI = 1.39–2.13), lower perioperative mortality (OR= 8.12, 95 % CI= 3.45–36.7) and fewer complications than CFR (OR= 3.68, 95 % CI= 2.47–5.42).</div></div><div><h3>Conclusion</h3><div>In this MAIC study based on the 2 largest cohorts of sinonasal cancer with skull base invasion, EEA offered comparable oncologic outcomes to CFR with reduced morbidity, supporting it as a valid alternative when performed in expert centres.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115382"},"PeriodicalIF":7.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp","authors":"Volkan Beylergil ,&nbsp;Laura Collins ,&nbsp;Lawrence H. Schwartz ,&nbsp;Thomas Eche ,&nbsp;Binsheng Zhao ,&nbsp;Stephane Champiat ,&nbsp;Richard Carvajal ,&nbsp;Shaad E. Abedin ,&nbsp;Laurent Dercle","doi":"10.1016/j.ejca.2025.115386","DOIUrl":"10.1016/j.ejca.2025.115386","url":null,"abstract":"<div><h3>Study aim</h3><div>Tebentafusp, a bispecific fusion protein consisting of affinity-enhanced T cell receptor fused to anti-CD3 effector, has shown overall survival (OS) benefits across all RECIST response categories, including progressive disease (PD). In a phase 2 trial (NCT02570308) for advanced uveal melanoma (mUM), 35 % of PD patients experienced ≥ 0.5 log ctDNA reduction, resulting in a median overall survival (OS) of ∼17 months, compared to ∼8 months in the non-ctDNA reduction group.</div></div><div><h3>Methods</h3><div>A total of 34 of 127 2L+ mUM patients with PD were split into two groups based on absence or presence of ctDNA reduction (≥0.5 log reduction). Lesions from CT and MRI scans were analyzed using radiomics features at baseline and week eight, yielding two machine-learning-derived patient signatures (16 features). Performance of per-patient analysis (n = 32) and per-lesion analysis (n = 148) was assessed using ROC AUC (95 % confidence interval [CI]).</div></div><div><h3>Results</h3><div>In the per-patient analysis, a volumetric signature classified patients into groups with ROC AUC of 0.71 [0.53–0.90] with 63 % specificity and 81 % sensitivity at the optimal threshold (0.57). In the per-lesion analysis, a radiomic signature reached an ROC AUC of 0.70 [0.58–0.81] with 66 % specificity and 74 % sensitivity at the optimal threshold (0.53). Group B had lower baseline tumor lesion volume (ROC AUC=0.65), distinct baseline (ROC AUC=0.66), and change by week eight (ROC AUC=0.66/0.69 on CT/MRI) in tumor heterogeneity.</div></div><div><h3>Conclusion</h3><div>Radiomic analysis accurately predicted ctDNA reduction in PD patients at both the patient and lesion level. The most influential predictor was decreased tumor heterogeneity observed on CT/MRI.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115386"},"PeriodicalIF":7.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}